Eribulin mesylate
Contents
Description
Eribulin mesylate is a microtubule dynamics inhibitor approved for metastatic breast cancer and unresectable or metastatic liposarcoma. It is a synthetic analog of halichondrin B, derived from a marine sponge, that inhibits microtubule growth without affecting depolymerization. Clinical trials have demonstrated improved overall survival in patients with advanced liposarcoma who received prior anthracycline-based chemotherapy.
Indications & Therapeutic Use
metastatic breast cancer, unresectable or metastatic liposarcoma, metastatic leiomyosarcoma
Linked Diseases:
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Eribulin mesylate — GNH India
52 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | eribulin mesylate |
| Brands | 1 brand available |
| Active Ingredient | eribulin mesylate |
| Drug Class | metastatic breast cancer |
| Manufacturer | Eisai |
| Dosage Forms | IV injection 0.5mg/mL (2mg/4mL vials) |
| Medical Code | L01XX41 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT01327885 |
| Countries | 9 countries |